Zymeworks, Inc. (ZYME)
25.15
-0.69
(-2.67%)
USD |
NASDAQ |
Nov 18, 12:41
Zymeworks Enterprise Value : 2.403B for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 2.403B |
| November 16, 2026 | 2.447B |
| November 13, 2026 | 2.432B |
| November 12, 2026 | 2.448B |
| November 11, 2026 | 2.635B |
| November 10, 2026 | 2.806B |
| November 09, 2026 | 2.759B |
| November 06, 2026 | 2.675B |
| November 05, 2026 | 2.611B |
| November 04, 2026 | 2.769B |
| November 03, 2026 | 2.711B |
| November 02, 2026 | 2.629B |
| October 30, 2026 | 2.602B |
| October 29, 2026 | 2.609B |
| October 28, 2026 | 2.622B |
| October 27, 2026 | 2.619B |
| October 26, 2026 | 2.584B |
| October 23, 2026 | 2.574B |
| October 22, 2026 | 2.589B |
| October 21, 2026 | 2.566B |
| October 20, 2026 | 2.480B |
| October 19, 2026 | 2.381B |
| October 16, 2026 | 2.345B |
| October 15, 2026 | 2.396B |
| October 14, 2026 | 2.326B |
| Date | Value |
|---|---|
| October 13, 2026 | 2.348B |
| October 12, 2026 | 2.366B |
| October 09, 2026 | 2.399B |
| October 08, 2026 | 2.361B |
| October 07, 2026 | 2.452B |
| October 06, 2026 | 2.389B |
| October 05, 2026 | 2.429B |
| October 02, 2026 | 2.353B |
| October 01, 2026 | 2.412B |
| September 30, 2026 | 2.450B |
| September 29, 2026 | 1.955B |
| September 28, 2026 | 1.950B |
| September 25, 2026 | 1.906B |
| September 24, 2026 | 1.927B |
| September 23, 2026 | 1.977B |
| September 22, 2026 | 1.982B |
| September 21, 2026 | 1.927B |
| September 18, 2026 | 1.910B |
| September 17, 2026 | 1.975B |
| September 16, 2026 | 1.886B |
| September 15, 2026 | 1.873B |
| September 14, 2026 | 1.930B |
| September 11, 2026 | 1.886B |
| September 10, 2026 | 1.900B |
| September 09, 2026 | 1.952B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 587.74B |
| Faeth Therapeutics, Inc. | 65.73M |
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 173.70M |
| Revenue (Quarterly) | 256.46M |
| Total Expenses (Quarterly) | 82.76M |
| EPS Diluted (Quarterly) | 2.278 |
| Gross Profit Margin (Quarterly) | 99.01% |
| Profit Margin (Quarterly) | 67.73% |
| Earnings Yield | 2.08% |
| Operating Earnings Yield | 2.35% |
| Normalized Earnings Yield | 2.088 |